Dermal Filler Comparison Guide by Type, Area & Longevity

HA fillers dominate practice revenue because they're versatile, reversible (hyaluronidase available), and familiar to patients. The key variable is crosslinking density and particle size. Tightly crosslinked, larger-particle HA (e.g., Juvéderm Ultra Plus, Restylane Lyft) resists diffusion and lasts 9–12 months in high-movement zones like lips and nasolabial folds. Lighter, smaller-particle HA (Juvéderm Volbella, Restylane Silk) spreads more, suits delicate areas (lips, tear troughs), and lasts 6–9 months. Mid-range formulations (Juvéderm Voluma, Restylane Defyne) bridge the gap for cheek and midface work, lasting 12+ months. Cost per syringe typically ranges from $8–15 at wholesale (Allergan Aesthetics and Galderma dominate pricing), meaning retail margins of 40–60% are standard. Stock depth in HA—at least 3–4 viscosities—is non-negotiable; patient expectation and clinical need vary dramatically by area.

Poly-L-lactic acid (PLLA, Sculptra) and calcium hydroxylapatite (CaHA, Radiesse) stimulate collagen remodeling rather than adding volume directly. PLLA requires 2–3 treatment sessions spaced 4–6 weeks apart; results peak at 3–4 months and persist 2+ years. CaHA works faster (results visible in days), lasts 12–18 months, and suits single-session correction. Both command higher per-syringe cost ($15–25 wholesale) but justify premium pricing to patients because longevity and gradual, natural-looking improvement reduce repeat-visit frequency. Biostimulators excel in the lower face, temples, and cheeks where volume loss is structural; they're less ideal for fine lines or dynamic wrinkles. Educate patients upfront: PLLA requires commitment and patience; CaHA is faster but shorter-lived than PLLA. Radiesse's radiopacity (visible on imaging) is a minor liability in some practices but rarely a clinical issue. Stock both if your patient base skews toward longevity-seeking clients; PLLA especially attracts high-LTV patients willing to invest in multi-session protocols.

Recent FDA approvals have expanded the HA toolkit. Skinvive by Juvéderm (approved 2024 for neck appearance) is a dilute, low-viscosity HA designed for superficial placement and skin quality improvement rather than volume; it's a new revenue stream for practices targeting the neck and décolletage. RHA (Resilient Hyaluronic Acid) fillers—RHA 2, RHA 3, RHA 4—use non-crosslinked HA that mimics natural tissue elasticity; they're marketed for dynamic zones (lips, perioral) and last 12+ months. Restylane Contour (Galderma) received FDA approval for temple hollowing, filling a specific anatomical niche. These specialty products command premium pricing (often $20+ per syringe retail) because they're newer, have narrower indications, and appeal to patients seeking cutting-edge options. Stock selectively: one RHA viscosity and Skinvive make sense if your patient mix includes aesthetic refinement seekers; Restylane Contour if temple work is part of your volume.

Filler longevity is not universal; placement anatomy and patient metabolism dictate duration. Lips and perioral: high movement, rapid metabolism—expect 6–8 months even with robust HA. Use smaller-particle, less-crosslinked HA (Volbella, Silk) to avoid overfilling and lumpiness. Nasolabial folds and marionette lines: moderate movement, 9–12 months typical with mid-range HA (Defyne, Ultra). Cheeks and midface: lower movement, 12–18 months with Voluma, Lyft, or CaHA. Tear troughs: delicate tissue, risk of Tyndall effect (blue hue) with thick HA—use ultra-fine formulations (Silk, Volbella). Temples and jawline: structural volume, 12+ months with PLLA or CaHA; HA also works but requires larger volumes. Patient expectations often exceed reality; set them early: "Most fillers last 9–12 months; lips fade faster because they move constantly." This conversation protects your reputation and justifies maintenance scheduling.

Filler economics hinge on wholesale cost, rebate programs, and retail pricing power. Allergan Aesthetics (Juvéderm, Voluma) and Galderma (Restylane, Radiesse) control ~70% of the HA market; both offer volume-based rebates through Alle (Allergan) and Aspire (Galderma). Buying 100+ syringes annually can reduce per-unit cost by 10–20%. Evolus (Nucelis RHA, Evolus Rewards program) is smaller but aggressive on pricing for practices committing to volume. Retail pricing varies by geography and competition: urban markets may sustain $600–800 per syringe; suburban/rural practices often price $400–600. Gross margin per syringe is typically 50–70%, but net margin after staff time, waste, and overhead is 30–40%. Stock rotation matters: HA has a 2-year shelf life; PLLA and CaHA are stable longer. Overstock ties up capital; understock loses revenue. Track per-area usage (e.g., "We use 40 syringes of Voluma per month") to forecast demand and negotiate rebates intelligently.

All FDA-cleared dermal fillers carry specific indications; staying within them protects your license and malpractice insurance. Juvéderm Ultra is cleared for nasolabial folds; off-label use in lips or tear troughs is legal but requires informed consent and documentation. Radiesse is cleared for hand rejuvenation and nasolabial folds; temple use is off-label. PLLA (Sculptra) is cleared for HIV-related lipoatrophy and facial volume loss; cosmetic use is off-label but routine. Document the indication, the product, the lot number, and the volume injected in every chart. If a complication arises (vascular occlusion, granuloma, allergic reaction), your chart is your defense. Hyaluronidase (Vitrase, Hylenex) should be stocked in every practice offering HA; it's the antidote to overcorrection or vascular compromise. Train all injectors on recognition and management of vascular events—blanching, pain, skin necrosis—and have a protocol. Malpractice carriers increasingly scrutinize filler complications; clear documentation and rapid intervention are non-negotiable.